Submit Deal

ARCUS BIOSCIENCES

Summary

Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 415 M

Avg. Deal Size£ 207 M

Market Context

Senior Management

Terry Rosen
CEO
Katherine Bock
Communications Director
Pia Eaves
Investor Contact

Sort

morgan stanley

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 163 M

Total Value

venable

HQ - Washington

legal advisors (1)

1 Shared Deal

1 Opposite

£ 163 M

Total Value

td cowen

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 163 M

Total Value

covington & burling

HQ - Washington DC

legal advisors (1)

1 Shared Deal

1 Opposite

£ 163 M

Total Value

skadden arps slate meagher & flom

HQ - New York

legal advisors (1)

1 Shared Deal

1 Opposite

£ 163 M

Total Value

citigroup

HQ - New York

financial advisors (1)

1 Shared Deal

1 For

£ 163 M

Total Value

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 For

£ 163 M

Total Value

jp morgan

HQ - New York

financial advisors (1)

1 Shared Deal

1 For

£ 252 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy